Shigeki Kakunaga

Suita, 5650871, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Establishment of a ZFP64::NCOA3 fusion-positive spindle cell/sclerosing rhabdomyosarcoma organoid model and evaluation of fusion-gene dependency.

Establishment of a ZFP64::NCOA3 fusion-positive spindle cell/sclerosing rhabdomyosarcoma organoid model and evaluation of fusion-gene dependency.

Journal: Human cell
Published: June 18, 2026

Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability.

Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability.

Journal: Human cell
Published: April 13, 2026

Chondrosarcoma organoids reveal SHH pathway activation driven by PTCH1 and BCOR alterations.

Chondrosarcoma organoids reveal SHH pathway activation driven by PTCH1 and BCOR alterations.

Journal: Scientific reports
Published: October 10, 2025

Dermatofibrosarcoma Protuberans With a Novel FBN1::PDGFD Fusion: Expanding the Molecular Spectrum.

Dermatofibrosarcoma Protuberans With a Novel FBN1::PDGFD Fusion: Expanding the Molecular Spectrum.

Journal: Journal of cutaneous pathology
Published: June 29, 2025

Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway.

Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway.

Journal: Human cell
Published: June 25, 2025

Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression.

Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression.

Journal: Scientific reports
Published: June 11, 2025

Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.

Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.

Journal: Current oncology (Toronto, Ont.)
Published: January 04, 2025

Lorlatinib for the Treatment of Inflammatory Myofibroblastic Tumor after Allogeneic Hematopoietic Stem Cell Transplantation.

Lorlatinib for the Treatment of Inflammatory Myofibroblastic Tumor after Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Internal medicine (Tokyo, Japan)
Published: July 24, 2024

Efficacy of surgery in the management of multiple recurrences of retroperitoneal dedifferentiated liposarcoma.

Efficacy of surgery in the management of multiple recurrences of retroperitoneal dedifferentiated liposarcoma.

Journal: World journal of surgical oncology
Published: June 03, 2024

Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).

Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).

Journal: Cancer
Published: March 21, 2024

Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report.

Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report.

Journal: Molecular and clinical oncology
Published: February 06, 2024

A case of pelvic EWSR1-PATZ1 fusion sarcoma treated with carbon ion radiotherapy.

A case of pelvic EWSR1-PATZ1 fusion sarcoma treated with carbon ion radiotherapy.

Journal: Radiology case reports
Published: February 05, 2024
Showing 1-12 of 40

Last Updated: 09/26/2026